237 related articles for article (PubMed ID: 18183009)
1. We speak for small biotech.
Sherwin SA
Nat Biotechnol; 2008 Jan; 26(1):27. PubMed ID: 18183009
[No Abstract] [Full Text] [Related]
2. We speak for small biotech.
Vanhemelrijck J
Nat Biotechnol; 2008 Jan; 26(1):27-8. PubMed ID: 18183008
[No Abstract] [Full Text] [Related]
3. Who speaks for small biotech?
Nat Biotechnol; 2007 Jul; 25(7):693. PubMed ID: 17621276
[No Abstract] [Full Text] [Related]
4. Insights into US public biotech sector using patenting trends.
Aggarwal S; Gupta V; Bagchi-Sen S
Nat Biotechnol; 2006 Jun; 24(6):643-51. PubMed ID: 16763590
[TBL] [Abstract][Full Text] [Related]
5. The development of China's medical biotech industry needs to be driven by innovation.
Yu Z; Dai Y
Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752
[TBL] [Abstract][Full Text] [Related]
6. In pursuit of patents: 21st century challenges.
Blatt RJ
J Biolaw Bus; 1998; 1(4):4-7. PubMed ID: 11657745
[No Abstract] [Full Text] [Related]
7. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
8. Biotech patenting slows in 2004.
Lawrence S
Nat Biotechnol; 2005 Oct; 23(10):1198. PubMed ID: 16211048
[No Abstract] [Full Text] [Related]
9. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
Gruber AC
Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
[TBL] [Abstract][Full Text] [Related]
10. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
11. European exploitation of biotechnology-do government policies help? A recent survey of public spending on biotechnology in Europe suggests that money alone cannot stimulate growth of the sector.
Senker J; Enzing C; Joly PB; Reiss T
Nat Biotechnol; 2000 Jun; 18(6):605-8. PubMed ID: 10835596
[No Abstract] [Full Text] [Related]
12. The morality of biotech patents: differing legal obligations in Europe?
Ford R
Eur Intellect Prop Rev; 1997 Jun; 19(6):315-8. PubMed ID: 16538738
[No Abstract] [Full Text] [Related]
13. Wrong map: why public science can't really be public.
Mukherjee S
New Repub; 2000 May; 222(19):14-5. PubMed ID: 12465651
[No Abstract] [Full Text] [Related]
14. Biotech as Bush bows out.
Lorenzo A
Nat Biotechnol; 2008 Jan; 26(1):15-8. PubMed ID: 18183006
[No Abstract] [Full Text] [Related]
15. How should public policy respond to the challenges of modern biotechnology?
Cantley M
Curr Opin Biotechnol; 2004 Jun; 15(3):258-63. PubMed ID: 15193337
[TBL] [Abstract][Full Text] [Related]
16. Sustainability and the balancing of the health care and innovation agendas: the commercialization of genetic research.
Caulfield T
Sask Law Rev; 2003; 66(2):629-45. PubMed ID: 15212021
[No Abstract] [Full Text] [Related]
17. Open-source biology.
Nature; 2004 Sep; 431(7008):491. PubMed ID: 15457218
[No Abstract] [Full Text] [Related]
18. Biologists launch 'open-source movement'.
Dennis C
Nature; 2004 Sep; 431(7008):494. PubMed ID: 15457220
[No Abstract] [Full Text] [Related]
19. Biotech patenting matures.
Lawrence S
Nat Biotechnol; 2004 Oct; 22(10):1202. PubMed ID: 15470446
[No Abstract] [Full Text] [Related]
20. Biotech patenting upturn.
Lawrence S
Nat Biotechnol; 2006 Oct; 24(10):1190. PubMed ID: 17033646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
